Nu Skin Earnings Call: Profits Rise, Outlook Cautious
Nu Skin Enterprises ((NUS)) has held its Q4 earnings call. Read on for the main highlights of the call.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nu Skin Enterprises’ latest earnings call struck a cautiously optimistic tone, pairing a sharp rebound in profitability and healthier margins with a frank acknowledgment of softer top-line trends and execution risks. Management highlighted strong 2025 earnings leverage and a fortified balance sheet, but tempered enthusiasm with conservative 2026 guidance, FX headwinds, and uncertainty around new growth platforms.
Robust EPS Rebound Driven by Margin Gains
Adjusted EPS for 2025 jumped to $1.27 from $0.84 a year earlier, a gain of about 51% that outpaced revenue trends. Management credited gross margin expansion, tighter selling expense, and disciplined G&A as the main drivers of the earnings recovery.
Revenue Holds Within Targets Despite Growth Headwinds
Full-year 2025 revenue came in at $1.49 billion, and fourth-quarter sales reached $370 million, both landing inside prior guidance ranges. While not signaling robust growth, hitting targets helped underpin management’s message of improving operational control.
Core Gross Margin Expansion Signals Healthier Fundamentals
Core Nu Skin gross margin reached 77.4% for 2025, up roughly 80 basis points year over year, with Q4 core margin at 77.6%, up 100 basis points. These gains suggest better product mix and pricing discipline in the direct-selling franchise, even as the broader portfolio creates some headline pressure.
Operating Margin Upside and Expense Discipline
Adjusted operating margin improved to 6.7% for the year, up 140 basis points, with Q4 at 6.3%, showing structural cost progress. Selling expense in Q4 fell to 35.5% from 37.1%, reflecting optimization, though management cautioned that core selling costs remain high.
Net Cash Position and Stronger Cash Generation
Nu Skin ended Q4 with about $240 million in cash and reduced debt to $224 million, moving into a net cash position that boosts financial flexibility. Operating cash flow of $80.3 million for 2025 underscored the improved earnings quality and balance sheet resilience.
Ongoing Capital Returns to Shareholders
The company returned roughly $11 million via dividends and $20 million through share repurchases over the year, underscoring confidence in cash generation. With $142.3 million still authorized for buybacks, management retains meaningful capacity to support the stock if conditions warrant.
Prism IO: Building a Massive Wellness Data Platform
Management showcased Prism IO, an intelligent-wellness ecosystem built on nearly 400 million carotenoid data points from 21 million scans and over 1 billion IoT readings. Launched late 2025, the platform aims to place more than 100,000 devices in 2026 and to reach 10 million households by 2030.
Emerging Markets and RISE Manufacturing Expansion
Nu Skin reported continued momentum in Latin America and the start of premarket operations in India in mid-November. These efforts tie into a broader strategy to capture high-growth emerging markets while scaling RISE manufacturing capabilities for future product and device demand.
Conservative 2026 Outlook Highlights Top-Line Pressure
For 2026, revenue is guided to $1.35 billion to $1.50 billion, including about $13 million to $15 million in FX drag, with EPS expected at $0.80 to $1.20, down from 2025’s $1.27. Management framed the outlook as deliberately cautious, reflecting uneven visibility and multiple macro and execution headwinds.
Q4 Consolidated Gross Margin Softness
Consolidated gross margin in Q4 slipped to 70.7% from 71.4% a year earlier, a decline of roughly 70 basis points. The pressure largely stemmed from mix shifts between RISE entities and Nu Skin segments plus seasonal promotions, partly masking the strength in core margins.
Higher Tax Rate to Weigh on 2026 EPS
Nu Skin’s 2025 effective tax rate was 18.8% thanks to an R&D tax credit that lowered tax by about $8.1 million. For 2026, the company assumes a roughly 35% tax rate, creating a below-the-line headwind that dampens EPS even as operations continue to improve.
Persistent FX Headwinds Trim Revenue and Earnings
Foreign currency reduced Q4 results by about $1 million and full-year 2025 by roughly $13.4 million. Management built a further $13 million to $15 million FX headwind, or about 1%, into 2026 guidance, keeping a lid on reported growth despite underlying progress.
Prism IO Monetization Still an Open Question
While the company has ambitious device placement and household penetration goals, Prism IO remains in early rollout with only about a month of live placements at the time of the call. Management did not provide detailed subscription conversion or revenue metrics, leaving investors guessing about timing and scale of monetization.
India Entry Brings Promise and Execution Risk
Premarket work in India is underway, but management highlighted structural challenges such as high import duties, the need for local manufacturing, and complex logistics and digital infrastructure. They also characterized Indian consumers as financially conservative, implying longer sales cycles and modest near-term revenue expectations.
High Core Selling Costs Limit Near-Term Leverage
Core Nu Skin selling expense stayed elevated at about 40.3% for the year, with Q4 at 40.8%, even as some efficiencies emerged. Management expects selling expense to hover near 40% as they drive adoption of a new compensation plan, constraining operating leverage until volumes scale.
Seasonality and Earnings Volatility in 2026
Nu Skin flagged pronounced seasonality, with Q1 2026 expected to be the weakest quarter and EPS guided to just $0.10 to $0.20. Management expects stronger performance in the back half of the year as Prism IO becomes more broadly available to consumers and device placements ramp.
Guidance Underscores Rebuild Year with Back-Half Skew
Looking ahead, the company guided 2026 revenue to $1.35 billion to $1.50 billion and adjusted EPS to $0.80 to $1.20 on a roughly 35% tax rate, with Q1 revenue seen at $320 million to $340 million. Management emphasized that 2025’s margin gains and net cash position set a foundation, while Prism IO device revenue potential and subscriptions are expected to tilt growth toward the second half and beyond.
Nu Skin’s call painted a picture of a company rebuilding profitability and investing in new growth engines while navigating a choppy revenue environment. For investors, the story is now less about immediate top-line acceleration and more about whether management can steadily monetize Prism IO, execute in markets like India, and convert today’s margin gains into durable, long-term value.
